EGFR and neoplasm: Ourhypothesis for this phenomenon is that receptor competition from excessblocking agents caused EGFR-bound ABY-029 throughout the body (liver,kidney, skin, etc.)to be released back into the blood, increasingmeasured signal in tumor and muscle.